Rewards for abstaining from cannabis use
The Cost-effectiveness of Contingency Management Compared to Standard Cognitive Behavioral Treatment for Treating Cannabis Use Disorder in Youth: A Randomized Controlled Trial
This study is testing whether a rewards program or therapy is better at helping young people aged 16-22 quit using cannabis and stay abstinent over a year.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 154 (estimated) |
| Ages | 16 Years to 22 Years |
| Sex | All |
| Sponsor | Parnassia Addiction Research Centre Academic / other |
| Locations | 5 sites (Amsterdam and 4 other locations) |
| Trial ID | NCT05836207 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness and cost-effectiveness of contingency management (CM) compared to cognitive behavioral therapy (CBT) for treating cannabis use disorder (CUD) in youths aged 16-22. Participants will be randomly assigned to either 12 weeks of outpatient CM or CBT, with assessments conducted at multiple time points to evaluate cannabis abstinence and treatment outcomes. The study aims to determine which approach leads to more days of abstinence and is more cost-effective over a 12-month follow-up period.
Who should consider this trial
Good fit: Ideal candidates are youths aged 16-22 who are seeking treatment for cannabis use disorder and are willing to commit to abstinence.
Not a fit: Patients with acute psychosis or suicidality, or those who do not speak Dutch, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a more effective treatment option for young individuals struggling with cannabis use disorder.
How similar studies have performed: Previous studies have shown promise in using contingency management for substance use disorders, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Youths (16-22 years) seeking treatment for a primary CUD * Regular cannabis use (≥14 days) in past 4 weeks * Intention to cease cannabis use during intervention * Able and willing to attend the treatment center and submit urine samples under supervision twice-weekly * Informed consent. Exclusion Criteria: * Health contra-indications (e.g., acute psychosis/suicidality) * Insufficient Dutch language.
Where this trial is running
Amsterdam and 4 other locations
- Jellinek, Stichting Arkin B.V. — Amsterdam, Netherlands (Recruiting)
- IrisZorg — Arnhem, Netherlands (Recruiting)
- Antes Youz — Rotterdam, Netherlands (Recruiting)
- Brijder — The Hague, Netherlands (Recruiting)
- Novadic-Kentron — Vught, Netherlands (Recruiting)
Study contacts
- Principal investigator: Renske Spijkerman, PhD — Parc
- Study coordinator: Eva Garssen, MsC
- Email: e.garssen@brijder.nl
- Phone: +3188 358 20 34
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.